The Mental Development Investigation Center (CIDEM), whose Director and Principal Investigator is Dr. Luis Carlos Sancho Torres, was created in the year 2000. It is dedicated to clinical research in psychiatry.
Currently, the CIDEM has a private clinic to assess patients, with independent areas for conducting physical examinations, laboratory sampling, and other procedures such as electrocardiograms, weight, height, vital signs, etc.
It has a large comfortable waiting room and an area for meetings for the staff of the site, as well as for the carrying out assessments of the various scientific committees that are working on, or performing, the respective clinical monitoring of our sponsors.
The site has all the technological advances required for this activity such as wireless broadband Internet, dedicated fax line 24 hours a day, a protected file records system designed to protect all the files from our previous clinical trials, as well as an environmentally, temperature-controlled storage area for medicines being used in the studies, and an exclusive refrigerator for study drugs that require it, etc.
Over time we have managed to form a solid, united team that consists of two medical-psychiatrists, two clinical psychologists, a professional in pharmaceuticals and a clinical coordinator. All members of the team have extensive experience in their respective areas; management of the psychological scales most used in research today, and are updated with the latest courses in GCP, etc.
Having a full-time professional in pharmacy at the research site is one of our advantages over other centers of study as we can import medicines for the investigations in cases where the sponsoring company is not represented in Costa Rica.
CIDEM is one of three research centers established ex-profeso, to conduct clinical trials in psychiatry in Costa Rica, with the safety and comfort for the patient and the representatives of the sponsoring houses, and where studies of merit and value can be conducted in a proper environment.
We have handled Phase II, III and IV studies in almost all psychiatric disorders. Our offices are also designed to manage clinical trials in Neurology as there are two renowned neurologists associated with our staff.
Clinical Research: 2001 – Present
FD1-HIS-S015. “Changing schizophrenic patients from Haloperidol to Olanzapine: An open study.” Sponsored by: Eli-Lilly, Principal Investigator
MK-0869 No.62. “Multicenter, double-blind acute phase and extension, placebo-controlled, active comparator of two doses of MK-0869, for the treatment of patients suffering from major depressive disorder.” Sponsored by Merck Sharp & Dohme, Principal Investigator
MK-0869 No.65. “Multi-center, double-blind, with placebo to test the efficacy in the maintenance of antidepressant effect of MK-0869 in patients with depressive disorder.” Sponsored by Merck Sharp & Dohme, Sub-Investigator
NKF100110. “Randomized, double-blind, placebo-controlled, parallel-group, with forced dose titration to evaluate the efficacy and safety of GW679769 and Paroxetine in patients with social anxiety.” Sponsored by GlaxoSmithKline, Principal Investigator
NKF100096. “A randomized, double-blind, double dummy, parallel group, placebo-controlled forced dose adjustment to evaluate the efficacy and safety of GW679769 and Paroxetine in Subjects with Major Depressive Disorder.” Sponsored by GlaxoSmithKline, Principal Investigator
RO76477-BIM-3004. “An international, multi-center, double-blind, randomized, parallel-group, placebo-controlled, Phase III study of the efficacy and safety of Quetiapine Fumarate (Seroquel™), single oral 300 mg or 600 mg dose) and Paroxetine as monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks.” Sponsored by Janssen. 2007. Secondary Investigator.
SND103288. “Multi-center, randomized, double-blind, parallel group, placebo-controlled active substance in Ten Weeks, Flexible Dose to Evaluate the Efficacy, Safety and Tolerability of Paroxetine GSK372475 or, Compared to Placebo in Adult Subjects Diagnosed with Disorder Major Depressive.” Principal Investigator